Vivimed Labs Past Earnings Performance
Past criteria checks 0/6
Vivimed Labs's earnings have been declining at an average annual rate of -56.8%, while the Pharmaceuticals industry saw earnings growing at 16.2% annually. Revenues have been declining at an average rate of 36.8% per year.
Key information
-56.8%
Earnings growth rate
-61.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -36.8% |
| Return on equity | -816.5% |
| Net Margin | -185.7% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Vivimed Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 1,733 | -3,219 | 336 | 0 |
| 31 Mar 23 | 1,881 | -3,285 | 351 | 0 |
| 31 Dec 22 | 2,121 | -809 | 335 | 0 |
| 30 Sep 22 | 2,124 | -862 | 333 | 0 |
| 30 Jun 22 | 2,226 | -875 | 343 | 0 |
| 31 Mar 22 | 2,386 | -676 | 386 | 0 |
| 31 Dec 21 | 2,176 | -768 | 375 | 0 |
| 30 Sep 21 | 4,438 | -1,026 | 979 | 0 |
| 30 Jun 21 | 6,129 | -930 | 1,425 | 0 |
| 31 Mar 21 | 8,713 | -719 | 1,969 | 0 |
| 31 Dec 20 | 10,688 | -1,112 | 2,659 | 0 |
| 30 Sep 20 | 9,863 | -937 | 2,371 | 0 |
| 30 Jun 20 | 10,462 | -1,064 | 2,337 | 0 |
| 31 Mar 20 | 10,671 | -1,091 | 2,412 | 0 |
| 31 Dec 19 | 11,828 | -485 | 2,425 | 0 |
| 30 Sep 19 | 12,332 | -56 | 2,361 | 0 |
| 30 Jun 19 | 13,193 | 391 | 2,451 | 0 |
| 31 Mar 19 | 13,381 | 574 | 2,486 | 0 |
| 31 Dec 18 | 12,727 | 686 | 2,292 | 0 |
| 30 Sep 18 | 13,255 | 787 | 2,392 | 0 |
| 30 Jun 18 | 12,389 | 825 | 2,130 | 0 |
| 31 Mar 18 | 11,953 | 779 | 2,026 | 0 |
| 31 Dec 17 | 13,377 | 1,819 | 3,045 | 0 |
| 30 Sep 17 | 13,978 | 2,138 | 3,023 | 0 |
| 30 Jun 17 | 14,131 | 2,186 | 1,820 | 0 |
| 31 Mar 17 | 14,700 | 2,140 | 1,942 | 0 |
| 31 Dec 16 | 13,702 | 1,196 | 3,041 | 0 |
| 30 Sep 16 | 13,390 | 903 | 2,923 | 0 |
| 30 Jun 16 | 13,813 | 874 | 2,887 | 0 |
| 31 Mar 16 | 13,456 | 837 | 2,839 | 0 |
| 31 Dec 15 | 13,605 | 890 | 2,753 | 676 |
| 30 Sep 15 | 13,743 | 866 | 2,848 | 676 |
| 30 Jun 15 | 13,510 | 791 | 1,827 | 0 |
| 31 Mar 15 | 13,801 | 721 | 2,910 | 0 |
| 31 Dec 14 | 14,003 | 651 | 1,777 | 394 |
| 30 Sep 14 | 13,918 | 636 | 2,163 | 394 |
| 30 Jun 14 | 13,766 | 635 | 744 | 0 |
| 31 Mar 14 | 13,590 | 664 | 2,557 | 394 |
| 31 Dec 13 | 12,909 | 703 | 1,679 | 323 |
| 30 Sep 13 | 12,277 | 683 | 1,582 | 323 |
| 30 Jun 13 | 11,889 | 774 | 516 | 0 |
| 31 Mar 13 | 11,207 | 836 | 1,352 | 323 |
| 31 Dec 12 | 10,640 | 909 | 1,023 | 214 |
Quality Earnings: 532660 is currently unprofitable.
Growing Profit Margin: 532660 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532660 is unprofitable, and losses have increased over the past 5 years at a rate of 56.8% per year.
Accelerating Growth: Unable to compare 532660's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 532660 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).
Return on Equity
High ROE: 532660 has a negative Return on Equity (-816.54%), as it is currently unprofitable.